Every year scientists, clinicians and patients from across the world gather to present and discuss the latest breast cancer research at the San Antonio Breast Cancer Symposium. We’ve gathered some highlights from 2019 conference:
CBCN had the opportunity to join researchers, clinicians, manufacturers and other patients at this annual European conference to learn the latest insights and findings in cancer research. Here’s the research that we found most interesting as breast cancer patients:
We’re sharing some interesting research results that we seen in the news recently.
We talked a lot on this blog last year about biosimilars; what they are and why it’s important to know about them. With the entry of biosimilars in the breast cancer treatment landscape due later this year, there are still questions and discussions about how it will affect current and future breast cancer patients. To help understand these questions and perspectives, we decided it was important to bring together those people who are impacted the most: patients and physicians.
It’s just the start of 2019 but we’re already thinking about fall and the federal election it brings with it. Last year, there was a lot of talk about the establishment of a national pharmacare plan. The federal government assembled a working group to study the best way a system like this would work in Canada.
In June 2015, I moved to London, Ontario and was recovering from a rather emotional and difficult time, having divorced in June 2014. I had moved from Sault Ste. Marie to be closer to my daughter with her husband and very young children. I would be seeing the rest of my family less often now – my parents, my two sisters, my daughter and her husband, and another granddaughter. and two step grandchildren.
It was just another typical morning in our house, trying to get my son fed and dressed before I take him to daycare. As I am multitasking, getting myself dressed and making sure my son is actually brushing his teeth, I notice he’s watching me. He’s still trying to process those two large scars across my chest. The incisions are still fresh and slowly healing and turning to scars. Scars that represent where my breasts once were but now is just an empty space. He finally pipes up. “When are your boobies going to grow back, Mommy?” He asks so innocently.
Inflammatory breast cancer (IBC) is a rare and aggressive form of the disease that doesn’t get a lot of attention. It’s tough to diagnose because of its unusual symptoms, and it’s more common in young women which makes it particularly tricky since the symptoms mimic that of mastitis, a common breast infection in new moms who breastfeed. Here’s what you need to know:
People have known about breast cancer since ancient times. For most of that time, there were no effective treatments. However, in the last 120 years, advances in surgical and medical treatments have meant that today, 98 percent of patients with localized breast cancer survive at least five years after diagnosis. The following timeline shows the development of breast cancer treatments.
“Abject terror floating in the back of my head.” That’s how Shelley Moore of St. Albert, Alberta describes her reaction to her 2014 diagnosis of Stage II triple negative breast cancer.
Biosimilar therapies have already been in use in Canada for a few years, mostly in the chronic disease and supportive care settings. But soon they will be used for treating cancer as well. There isn’t a lot of information about these new oncology biosimilars and it’s important that breast cancer patients are aware of how their treatment plans may be impacted by these new therapies. We explore some of the emerging biosimilar therapies that will be used to treat cancer patients soon.
Cancer related fatigue is so much more than just feeling tired from a long, hard day. Your cancer treatment can cause you to experience what feels like full body exhaustion. You’re so exhausted that you can’t get out of bed and no amount of rest will give you back your energy.
Febrile neutropenia, or FN, is a common and potentially serious side effect of chemotherapy treatment.